ACS Omega (May 2020)
Structural Basis of Activin Receptor-Like Kinase 2 (R206H) Inhibition by Bis-heteroaryl Pyrazole-Based Inhibitors for the Treatment of Fibrodysplasia Ossificans Progressiva Identified by the Integration of Ligand-Based and Structure-Based Drug Design Approaches
- Tomohiro Sato,
- Katsuhiko Sekimata,
- Naoki Sakai,
- Hisami Watanabe,
- Chiemi Mishima-Tsumagari,
- Tomonori Taguri,
- Takehisa Matsumoto,
- Yoshifumi Fujii,
- Noriko Handa,
- Akiko Tanaka,
- Mikako Shirouzu,
- Shigeyuki Yokoyama,
- Yoshinobu Hashizume,
- Kohei Miyazono,
- Hiroo Koyama,
- Teruki Honma
Affiliations
- Tomohiro Sato
- Drug Discovery Computational Chemistry Platform Unit, RIKEN Center for Biosystems Dynamics Research, Yokohama, Japan
- Katsuhiko Sekimata
- Drug Discovery Chemistry Platform Unit, RIKEN Center for Sustainable Resource Science, Wako, Saitama, Japan
- Naoki Sakai
- Drug Discovery Structural Biology Platform Unit, RIKEN Center for Biosystems Dynamics Research, Yokohama, Japan
- Hisami Watanabe
- Drug Discovery Structural Biology Platform Unit, RIKEN Center for Biosystems Dynamics Research, Yokohama, Japan
- Chiemi Mishima-Tsumagari
- Drug Discovery Structural Biology Platform Unit, RIKEN Center for Biosystems Dynamics Research, Yokohama, Japan
- Tomonori Taguri
- Drug Discovery Chemistry Platform Unit, RIKEN Center for Sustainable Resource Science, Wako, Saitama, Japan
- Takehisa Matsumoto
- Drug Discovery Structural Biology Platform Unit, RIKEN Center for Biosystems Dynamics Research, Yokohama, Japan
- Yoshifumi Fujii
- Crystallographic Drug Discovery Platform Unit, RIKEN Systems and Structural Biology Center, Yokohama, Japan
- Noriko Handa
- Crystallographic Drug Discovery Platform Unit, RIKEN Systems and Structural Biology Center, Yokohama, Japan
- Akiko Tanaka
- Drug Discovery Structural Biology Platform Unit, RIKEN Center for Biosystems Dynamics Research, Yokohama, Japan
- Mikako Shirouzu
- Drug Discovery Structural Biology Platform Unit, RIKEN Center for Biosystems Dynamics Research, Yokohama, Japan
- Shigeyuki Yokoyama
- Crystallographic Drug Discovery Platform Unit, RIKEN Systems and Structural Biology Center, Yokohama, Japan
- Yoshinobu Hashizume
- RIKEN Program for Drug Discovery and Medical Technology Platforms, Wako, Saitama, Japan
- Kohei Miyazono
- Department of Molecular Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
- Hiroo Koyama
- Drug Discovery Chemistry Platform Unit, RIKEN Center for Sustainable Resource Science, Wako, Saitama, Japan
- Teruki Honma
- Drug Discovery Computational Chemistry Platform Unit, RIKEN Center for Biosystems Dynamics Research, Yokohama, Japan
- DOI
- https://doi.org/10.1021/acsomega.9b04245
- Journal volume & issue
-
Vol. 5,
no. 20
pp. 11411 – 11423
Abstract
No abstracts available.